A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.
Evidence exists that partial tandem duplication levels from the MLL gene (MLL-PTD) are known indicators of poor prognosis in small groups of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following allogeneic hematopoietic stem cell transplant (allo-HSCT),1,2 and a new review3 explored using them to monitor for minimal residual disease status to predict disease relapse.
Writing in BMC Cancer, the authors noted, “Allo-HSCT is currently one of the curative therapies available for AML and MDS with excess blasts (MDS-EB). However, how the prognosis of patients with high levels of MLL-PTD after allo-HSCT, and whether MLL-PTD could be used as a reliable indicator for MRD monitoring in transplant patients remains unknown.”
Peking University People’s Hospital provided retrospective data on 48 patients with MLL-PTD AML (n = 33; 20 females) or MDS-EB (n = 15; 11 males) who underwent allo-HSCT at the facility, with their MLL-PTD measured at various time points—diagnosis, prior to allo-HSCT, several times after allo-HSCT—using real-time quantitative polymerase chain reaction (PCR). A cutoff level of detectable MLL-PTD/ABL greater than 0.08% indicated a positive MLL-PTD result, the authors wrote.
Overall, at the 3-year mark after allo-HSCT, the investigators saw the following mean (SD) incidence rates:
ROC curve analysis additionally produced the authors’ optimal cutoff value for prediction of relapse after allo-HSCT, MLL-PTD > 1.0%, for which statistical differences in the above 4 indicators (all P < .001) were seen at the 3-year mark compared with using MLL-PTD < 1.0%:
During the follow-up period (median, 26 [range, 0.7-56.0] months), the AML group had 7 treatment-related and 6 hematological relapse–related deaths; 2 patients died from the MDS-EB group.
When discussing their findings, the authors noted that although PCR-based gene detection methods have proven effective as a monitoring tool among patients with AML, most of this group still lack “effective, specific MRD molecular markers.” Physicians, they emphasized, need to watch more closely for posttransplant relapse among patients with MLL-PTD/ABL > 1%. It may also be necessary to shorten the MRD monitoring interval, they wrote.
“Our study indicated that MLL-PTD had a certain stability and could effectively reflect the change of tumor burden,” the authors concluded. “The expression level of MLL-PTD after transplantation can serve as an effective indicator for predicting relapse.”
Due to the small size of their study cohort of patients with MLL-PTD AML, they stress the need for ongoing research to confirm their findings.
Reference
1. Choi SM, Dewar R, Burke PW, Shao L. Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome. Haematologica. 2018;103(3):e131-e134. doi:10.3324/haematol.2017.185249
2. Sun Q-Y, Ding L-W, Koeffler HP. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia. 2017;31(1):1-10. doi:10.1038/leu.2016.160
3. Kong J, Gao M-G, Qin Y-Zm et al. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.BMC Cancer. Published online January 3, 2022. doi:10.1186/s12885-021-09051-5
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More